Eli Lilly’s Weight-Loss Drug is Cleared to Treat Diabetes in China

(Bloomberg) — China has approved Eli Lilly & Co.’s drug tirzepatide for use in treating diabetes, a move that will intensify the company’s rivalry with Novo Nordisk A/S over weight-loss drugs.

Tirzepatide was endorsed by Chinese regulators for treating adults with type 2 diabetes, the U.S. company announced in a statement Tuesday, though its use for chronic weight management is still under review.